Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

• Main Authors: Xiaolin Yu (Author), Sharad Ghamande (Author), Haitao Liu (Author), Lu Xue (Author), Shuhua Zhao (Author), Wenxi Tan (Author), Lijing Zhao (Author), Shou-Ching Tang (Author), Daqing Wu (Author), Hasan Korkaya (Author), Nita J. Maihle (Author), Hong Yan Liu (Author)
• Format: Book
• Published: Elsevier, 2018-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high...